Impact Factor
  • ISSN 1674-8301
  • CN 32-1810/R
Volume 37 Issue 3
May  2023
Turn off MathJax
Article Contents
Shu Liu, Xu Yang, Fei Chen, Zhiyou Cai. Dysfunction of the neurovascular unit in brain aging[J]. The Journal of Biomedical Research, 2023, 37(3): 153-165. doi: 10.7555/JBR.36.20220105
Citation: Shu Liu, Xu Yang, Fei Chen, Zhiyou Cai. Dysfunction of the neurovascular unit in brain aging[J]. The Journal of Biomedical Research, 2023, 37(3): 153-165. doi: 10.7555/JBR.36.20220105

Dysfunction of the neurovascular unit in brain aging

doi: 10.7555/JBR.36.20220105
More Information
  • Corresponding author: Zhiyou Cai, Department of Neurology, Chongqing General Hospital, No. 312 Zhongshan First Road, Yuzhong District, Chongqing 400013, China. Tel/Fax: +86-23-63515796/+86-23-63515796, E-mail: caizhiyou@ucas.ac.cn
  • Received: 2022-06-07
  • Revised: 2022-09-10
  • Accepted: 2022-09-22
  • Published: 2023-04-15
  • Issue Date: 2023-05-28
  • An emerging concept termed the neurovascular unit (NVU) underlines neurovascular coupling. It has been reported that NVU impairment can result in neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. Aging is a complex and irreversible process caused by programmed and damage-related factors. Loss of biological functions and increased susceptibility to additional neurodegenerative diseases are major characteristics of aging. In this review, we describe the basics of the NVU and discuss the effect of aging on NVU basics. Furthermore, we summarize the mechanisms that increase NVU susceptibility to neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. Finally, we discuss new treatments for neurodegenerative diseases and methods of maintaining an intact NVU that may delay or diminish aging.


  • CLC number: R741, Document code: A
    The authors reported no conflict of interests.
  • loading
  • [1]
    López-Otín C, Blasco MA, Partridge L, et al. The hallmarks of aging[J]. Cell, 2013, 153(6): 1194–1217. doi: 10.1016/j.cell.2013.05.039
    Rudnicka E, Napierała P, Podfigurna A, et al. The World Health Organization (WHO) approach to healthy ageing[J]. Maturitas, 2020, 139: 6–11. doi: 10.1016/j.maturitas.2020.05.018
    Hou Y, Dan X, Babbar M, et al. Ageing as a risk factor for neurodegenerative disease[J]. Nat Rev Neurol, 2019, 15(10): 565–581. doi: 10.1038/s41582-019-0244-7
    Grammas P, Martinez J, Miller B. Cerebral microvascular endothelium and the pathogenesis of neurodegenerative diseases[J]. Expert Rev Mol Med, 2011, 13: e19. doi: 10.1017/S1462399411001918
    Abbott NJ, Rönnbäck L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier[J]. Nat Rev Neurosci, 2006, 7(1): 41–53. doi: 10.1038/nrn1824
    Nutma E, van Gent D, Amor S, et al. Astrocyte and oligodendrocyte cross-talk in the central nervous system[J]. Cells, 2020, 9(3): 600. doi: 10.3390/cells9030600
    Wolf SA, Boddeke HWGM, Kettenmann H. Microglia in physiology and disease[J]. Annu Rev Physiol, 2017, 79: 619–643. doi: 10.1146/annurev-physiol-022516-034406
    Angelova DM, Brown DR. Microglia and the aging brain: are senescent microglia the key to neurodegeneration?[J]. J Neurochem, 2019, 151(6): 676–688. doi: 10.1111/jnc.14860
    Kabba JA, Xu Y, Christian H, et al. Microglia: housekeeper of the central nervous system[J]. Cell Mol Neurobiol, 2018, 38(1): 53–71. doi: 10.1007/s10571-017-0504-2
    Thurgur H, Pinteaux E. Microglia in the neurovascular unit: blood-brain barrier-microglia interactions after central nervous system disorders[J]. Neuroscience, 2019, 405: 55–67. doi: 10.1016/j.neuroscience.2018.06.046
    McTigue DM, Tripathi RB. The life, death, and replacement of oligodendrocytes in the adult CNS[J]. J Neurochem, 2008, 107(1): 1–19. doi: 10.1111/j.1471-4159.2008.05570.x
    Gaudet AD, Fonken LK. Glial cells shape pathology and repair after spinal cord injury[J]. Neurotherapeutics, 2018, 15(3): 554–577. doi: 10.1007/s13311-018-0630-7
    Peferoen L, Kipp M, van der Valk P, et al. Oligodendrocyte-microglia cross-talk in the central nervous system[J]. Immunology, 2014, 141(3): 302–313. doi: 10.1111/imm.12163
    Hawkins BT, Davis TP. The blood-brain barrier/neurovascular unit in health and disease[J]. Pharmacol Rev, 2005, 57(2): 173–185. doi: 10.1124/pr.57.2.4
    Miyazaki I, Asanuma M. Neuron-astrocyte interactions in parkinson's disease[J]. Cells, 2020, 9(12): 2623. doi: 10.3390/cells9122623
    Durkee CA, Araque A. Diversity and specificity of astrocyte-neuron communication[J]. Neuroscience, 2019, 396: 73–78. doi: 10.1016/j.neuroscience.2018.11.010
    Winkler EA, Sagare AP, Zlokovic BV. The pericyte: a forgotten cell type with important implications for Alzheimer's disease?[J]. Brain Pathol, 2014, 24(4): 371–386. doi: 10.1111/bpa.12152
    Armulik A, Abramsson A, Betsholtz C. Endothelial/pericyte interactions[J]. Circ Res, 2005, 97(6): 512–523. doi: 10.1161/01.RES.0000182903.16652.d7
    Stebbins MJ, Gastfriend BD, Canfield SG, et al. Human pluripotent stem cell-derived brain pericyte-like cells induce blood-brain barrier properties[J]. Sci Adv, 2019, 5(3): eaau7375. doi: 10.1126/sciadv.aau7375
    Teichert M, Milde L, Holm A, et al. Pericyte-expressed Tie2 controls angiogenesis and vessel maturation[J]. Nat Commun, 2017, 8: 16106. doi: 10.1038/ncomms16106
    Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis[J]. Nature, 2011, 473(7347): 298–307. doi: 10.1038/nature10144
    Rustenhoven J, Jansson D, Smyth LC, et al. Brain pericytes As mediators of neuroinflammation[J]. Trends Pharmacol Sci, 2017, 38(3): 291–304. doi: 10.1016/j.tips.2016.12.001
    De La Fuente AG, Lange S, Silva ME, et al. Pericytes stimulate oligodendrocyte progenitor cell differentiation during CNS remyelination[J]. Cell Rep, 2017, 20(8): 1755–1764. doi: 10.1016/j.celrep.2017.08.007
    Navarro R, Compte M, Álvarez-Vallina L, et al. Immune regulation by pericytes: modulating innate and adaptive immunity[J]. Front Immunol, 2016, 7: 480. https://pubmed.ncbi.nlm.nih.gov/27867386/
    Smyth LCD, Rustenhoven J, Park TIH, et al. Unique and shared inflammatory profiles of human brain endothelia and pericytes[J]. J Neuroinflammation, 2018, 15(1): 138. doi: 10.1186/s12974-018-1167-8
    Castelli V, Benedetti E, Antonosante A, et al. Neuronal cells rearrangement during aging and neurodegenerative disease: metabolism, oxidative stress and organelles dynamic[J]. Front Mol Neurosci, 2019, 12: 132. doi: 10.3389/fnmol.2019.00132
    Kirch C, Gollo LL. Single-neuron dynamical effects of dendritic pruning implicated in aging and neurodegeneration: towards a measure of neuronal reserve[J]. Sci Rep, 2021, 11(1): 1309. doi: 10.1038/s41598-020-78815-z
    Sandell JH, Peters A. Disrupted myelin and axon loss in the anterior commissure of the aged rhesus monkey[J]. J Comp Neurol, 2003, 466(1): 14–30. doi: 10.1002/cne.10859
    Halliwell B. Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment[J]. Drugs Aging, 2001, 18(9): 685–716. doi: 10.2165/00002512-200118090-00004
    Gounder SS, Kannan S, Devadoss D, et al. Impaired transcriptional activity of Nrf2 in age-related myocardial oxidative stress is reversible by moderate exercise training[J]. PLoS One, 2012, 7(9): e45697. doi: 10.1371/journal.pone.0045697
    Gu Y, Dee CM, Shen J. Interaction of free radicals, matrix metalloproteinases and caveolin-1 impacts blood-brain barrier permeability[J]. Front Biosci, 2011, 3(4): 1216–1231. https://pubmed.ncbi.nlm.nih.gov/21622267/
    DeBalsi KL, Hoff KE, Copeland WC. Role of the mitochondrial DNA replication machinery in mitochondrial DNA mutagenesis, aging and age-related diseases[J]. Ageing Res Rev, 2017, 33: 89–104. doi: 10.1016/j.arr.2016.04.006
    Mattson MP, Gleichmann M, Cheng A. Mitochondria in neuroplasticity and neurological disorders[J]. Neuron, 2008, 60(5): 748–766. doi: 10.1016/j.neuron.2008.10.010
    Harris JJ, Jolivet R, Attwell D. Synaptic energy use and supply[J]. Neuron, 2012, 75(5): 762–777. doi: 10.1016/j.neuron.2012.08.019
    Zhuo M, Gorgun MF, Englander EW. Augmentation of glycolytic metabolism by meclizine is indispensable for protection of dorsal root ganglion neurons from hypoxia-induced mitochondrial compromise[J]. Free Radic Biol Med, 2016, 99: 20–31. doi: 10.1016/j.freeradbiomed.2016.07.022
    Takahashi S. Metabolic compartmentalization between astroglia and neurons in physiological and pathophysiological conditions of the neurovascular unit[J]. Neuropathology, 2020, 40(2): 121–137. doi: 10.1111/neup.12639
    Bélanger M, Allaman I, Magistretti PJ. Brain energy metabolism: focus on astrocyte-neuron metabolic cooperation[J]. Cell Metab, 2011, 14(6): 724–738. doi: 10.1016/j.cmet.2011.08.016
    Abe T, Takahashi S, Suzuki N. Oxidative metabolism in cultured rat astroglia: effects of reducing the glucose concentration in the culture medium and of D-aspartate or potassium stimulation[J]. J Cereb Blood Flow Metab, 2006, 26(2): 153–160. doi: 10.1038/sj.jcbfm.9600175
    Pellerin L, Magistretti PJ. Glutamate uptake into astrocytes stimulates aerobic glycolysis: a mechanism coupling neuronal activity to glucose utilization[J]. Proc Natl Acad Sci U S A, 1994, 91(22): 10625–10629. doi: 10.1073/pnas.91.22.10625
    Mergenthaler P, Lindauer U, Dienel GA, et al. Sugar for the brain: the role of glucose in physiological and pathological brain function[J]. Trends Neurosci, 2013, 36(10): 587–597. doi: 10.1016/j.tins.2013.07.001
    Salminen A, Ojala J, Kaarniranta K, et al. Astrocytes in the aging brain express characteristics of senescence-associated secretory phenotype[J]. Eur J Neurosci, 2011, 34(1): 3–11. doi: 10.1111/j.1460-9568.2011.07738.x
    Bhat R, Crowe EP, Bitto A, et al. Astrocyte senescence as a component of Alzheimer's disease[J]. PLoS One, 2012, 7(9): e45069. doi: 10.1371/journal.pone.0045069
    Reinert A, Morawski M, Seeger J, et al. Iron concentrations in neurons and glial cells with estimates on ferritin concentrations[J]. BMC Neurosci, 2019, 20(1): 25. doi: 10.1186/s12868-019-0507-7
    Salami A, Papenberg G, Sitnikov R, et al. Elevated neuroinflammation contributes to the deleterious impact of iron overload on brain function in aging[J]. Neuroimage, 2021, 230: 117792. doi: 10.1016/j.neuroimage.2021.117792
    Stockwell BR, Friedmann Angeli JP, Bayir H, et al. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease[J]. Cell, 2017, 171(2): 273–285. doi: 10.1016/j.cell.2017.09.021
    Wang J, Song N, Jiang H, et al. Pro-inflammatory cytokines modulate iron regulatory protein 1 expression and iron transportation through reactive oxygen/nitrogen species production in ventral mesencephalic neurons[J]. Biochim Biophys Acta Mol Basis Dis, 2013, 1832(5): 618–625. doi: 10.1016/j.bbadis.2013.01.021
    Thomsen MS, Andersen MV, Christoffersen PR, et al. Neurodegeneration with inflammation is accompanied by accumulation of iron and ferritin in microglia and neurons[J]. Neurobiol Dis, 2015, 81: 108–118. doi: 10.1016/j.nbd.2015.03.013
    Damani MR, Zhao L, Fontainhas AM, et al. Age-related alterations in the dynamic behavior of microglia[J]. Aging Cell, 2011, 10(2): 263–276. doi: 10.1111/j.1474-9726.2010.00660.x
    Orre M, Kamphuis W, Osborn LM, et al. Acute isolation and transcriptome characterization of cortical astrocytes and microglia from young and aged mice[J]. Neurobiol Aging, 2014, 35(1): 1–14. doi: 10.1016/j.neurobiolaging.2013.07.008
    Koellhoffer EC, McCullough LD, Ritzel RM. Old maids: aging and its impact on microglia function[J]. Int J Mol Sci, 2017, 18(4): 769. doi: 10.3390/ijms18040769
    von Bernhardi R, Eugenín-von Bernhardi L, Eugenín J. Microglial cell dysregulation in brain aging and neurodegeneration[J]. Front Aging Neurosci, 2015, 7: 124. doi: 10.3389/fnagi.2015.00124
    Duncombe J, Lennen RJ, Jansen MA, et al. Ageing causes prominent neurovascular dysfunction associated with loss of astrocytic contacts and gliosis[J]. Neuropathol Appl Neurobiol, 2017, 43(6): 477–491. doi: 10.1111/nan.12375
    Mishra A, Reynolds JP, Chen Y, et al. Astrocytes mediate neurovascular signaling to capillary pericytes but not to arterioles[J]. Nat Neurosci, 2016, 19(12): 1619–1627. doi: 10.1038/nn.4428
    Bell RD, Winkler EA, Sagare AP, et al. Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and during brain aging[J]. Neuron, 2010, 68(3): 409–427. doi: 10.1016/j.neuron.2010.09.043
    Lourenço CF, Ledo A, Caetano M, et al. Age-dependent impairment of neurovascular and neurometabolic coupling in the hippocampus[J]. Front Physiol, 2018, 9: 913. doi: 10.3389/fphys.2018.00913
    Balbi M, Ghosh M, Longden TA, et al. Dysfunction of mouse cerebral arteries during early aging[J]. J Cereb Blood Flow Metab, 2015, 35(9): 1445–1453. doi: 10.1038/jcbfm.2015.107
    Fabiani M, Gordon BA, Maclin EL, et al. Neurovascular coupling in normal aging: a combined optical, ERP and fMRI study[J]. Neuroimage, 2014, 85: 592–607. doi: 10.1016/j.neuroimage.2013.04.113
    Graves SI, Baker DJ. Implicating endothelial cell senescence to dysfunction in the ageing and diseased brain[J]. Basic Clin Pharmacol Toxicol, 2020, 127(2): 102–110. doi: 10.1111/bcpt.13403
    Murugesan N, Demarest TG, Madri JA, et al. Brain regional angiogenic potential at the neurovascular unit during normal aging[J]. Neurobiol Aging, 2012, 33(5): 1004.e1–1004.e16. doi: 10.1016/j.neurobiolaging.2011.09.022
    Ungvari Z, Tucsek Z, Sosnowska D, et al. Aging-induced dysregulation of dicer1-dependent microRNA expression impairs angiogenic capacity of rat cerebromicrovascular endothelial cells[J]. J Gerontol A Biol Sci Med Sci, 2013, 68(8): 877–891. doi: 10.1093/gerona/gls242
    Senatorov VV JR, Friedman AR, Milikovsky DZ, et al. Blood-brain barrier dysfunction in aging induces hyperactivation of TGFβ signaling and chronic yet reversible neural dysfunction[J]. Sci Transl Med, 2019, 11(521): eaaw8283. doi: 10.1126/scitranslmed.aaw8283
    Cacheaux LP, Ivens S, David Y, et al. Transcriptome profiling reveals TGF-β signaling involvement in epileptogenesis[J]. J Neurosci, 2009, 29(28): 8927–8935. doi: 10.1523/JNEUROSCI.0430-09.2009
    Bar-Klein G, Cacheaux LP, Kamintsky L, et al. Losartan prevents acquired epilepsy via TGF-β signaling suppression[J]. Ann Neurol, 2014, 75(6): 864–875. doi: 10.1002/ana.24147
    Levy N, Milikovsky DZ, Baranauskas G, et al. Differential TGF-β signaling in glial subsets underlies IL-6-mediated epileptogenesis in Mice[J]. J Immunol, 2015, 195(4): 1713–1722. doi: 10.4049/jimmunol.1401446
    Montagne A, Barnes SR, Sweeney MD, et al. Blood-brain barrier breakdown in the aging human hippocampus[J]. Neuron, 2015, 85(2): 296–302. doi: 10.1016/j.neuron.2014.12.032
    Ivens S, Kaufer D, Flores LP, et al. TGF-β receptor-mediated albumin uptake into astrocytes is involved in neocortical epileptogenesis[J]. Brain, 2007, 130(2): 535–547. doi: 10.1093/brain/awl317
    Garwood CJ, Ratcliffe LE, Simpson JE, et al. Review: Astrocytes in Alzheimer's disease and other age-associated dementias: a supporting player with a central role[J]. Neuropathol Appl Neurobiol, 2017, 43(4): 281–298. doi: 10.1111/nan.12338
    Simpson JE, Ince PG, Haynes LJ, et al. Population variation in oxidative stress and astrocyte DNA damage in relation to Alzheimer-type pathology in the ageing brain[J]. Neuropathol Appl Neurobiol, 2010, 36(1): 25–40. doi: 10.1111/j.1365-2990.2009.01030.x
    Angelova DM, Brown DR. Altered processing of β-amyloid in SH-SY5Y cells induced by model senescent microglia[J]. ACS Chem Neurosci, 2018, 9(12): 3137–3152. doi: 10.1021/acschemneuro.8b00334
    Hickman SE, Allison EK, El Khoury J. Microglial dysfunction and defective β-amyloid clearance pathways in aging Alzheimer's disease mice[J]. J Neurosci, 2008, 28(33): 8354–8360. doi: 10.1523/JNEUROSCI.0616-08.2008
    Yamazaki Y, Kanekiyo T. Blood-brain barrier dysfunction and the pathogenesis of Alzheimer's disease[J]. Int J Mol Sci, 2017, 18(9): 1965. doi: 10.3390/ijms18091965
    Soto-Rojas LO, Pacheco-Herrero M, Martínez-Gómez PA, et al. The neurovascular unit dysfunction in Alzheimer's disease[J]. Int J Mol Sci, 2021, 22(4): 2022. doi: 10.3390/ijms22042022
    Garwood CJ, Simpson JE, Al Mashhadi S, et al. DNA damage response and senescence in endothelial cells of human cerebral cortex and relation to Alzheimer's neuropathology progression: a population-based study in the Medical Research Council Cognitive Function and Ageing Study (MRC-CFAS) cohort[J]. Neuropathol Appl Neurobiol, 2014, 40(7): 802–814. doi: 10.1111/nan.12156
    Procter TV, Williams A, Montagne A. Interplay between brain pericytes and endothelial cells in dementia[J]. Am J Pathol, 2021, 191(11): 1917–1931. doi: 10.1016/j.ajpath.2021.07.003
    Winkler EA, Sengillo JD, Bell RD, et al. Blood-spinal cord barrier pericyte reductions contribute to increased capillary permeability[J]. J Cereb Blood Flow Metab, 2012, 32(10): 1841–1852. doi: 10.1038/jcbfm.2012.113
    Yang AC, Stevens MY, Chen MB, et al. Physiological blood-brain transport is impaired with age by a shift in transcytosis[J]. Nature, 2020, 583(7816): 425–430. doi: 10.1038/s41586-020-2453-z
    Sengillo JD, Winkler EA, Walker CT, et al. Deficiency in mural vascular cells coincides with blood-brain barrier disruption in Alzheimer's disease[J]. Brain Pathol, 2013, 23(3): 303–310. doi: 10.1111/bpa.12004
    Montagne A, Nikolakopoulou AM, Zhao Z, et al. Pericyte degeneration causes white matter dysfunction in the mouse central nervous system[J]. Nat Med, 2018, 24(3): 326–337. doi: 10.1038/nm.4482
    Rucker HK, Wynder HJ, Thomas WE. Cellular mechanisms of CNS pericytes[J]. Brain Res Bull, 2000, 51(5): 363–369. doi: 10.1016/S0361-9230(99)00260-9
    Barker R, Ashby EL, Wellington D, et al. Pathophysiology of white matter perfusion in Alzheimer's disease and vascular dementia[J]. Brain, 2014, 137(5): 1524–1532. doi: 10.1093/brain/awu040
    Rajani RM, Quick S, Ruigrok SR, et al. Reversal of endothelial dysfunction reduces white matter vulnerability in cerebral small vessel disease in rats[J]. Sci Transl Med, 2018, 10(448): eaam9507. doi: 10.1126/scitranslmed.aam9507
    Desai BS, Schneider JA, Li J, et al. Evidence of angiogenic vessels in Alzheimer's disease[J]. J Neural Transm (Vienna), 2009, 116(5): 587–597. doi: 10.1007/s00702-009-0226-9
    Gonzalez-Rodriguez P, Zampese E, Surmeier DJ. Selective neuronal vulnerability in Parkinson's disease[J]. Prog Brain Res, 2020, 252: 61–89. https://pubmed.ncbi.nlm.nih.gov/32247375/
    Liang C, Wang TT, Luby-Phelps K, et al. Mitochondria mass is low in mouse substantia nigra dopamine neurons: implications for Parkinson's disease[J]. Exp Neurol, 2007, 203(2): 370–380. doi: 10.1016/j.expneurol.2006.08.015
    Fivenson EM, Lautrup S, Sun N, et al. Mitophagy in neurodegeneration and aging[J]. Neurochem Int, 2017, 109: 202–209. doi: 10.1016/j.neuint.2017.02.007
    Gredilla R, Bohr VA, Stevnsner T. Mitochondrial DNA repair and association with aging--an update[J]. Exp Gerontol, 2010, 45(7–8): 478–488. doi: 10.1016/j.exger.2010.01.017
    Youdim MBH, Stephenson G, Ben Shachar D. Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28[J]. Ann N Y Acad Sci, 2004, 1012: 306–325. doi: 10.1196/annals.1306.025
    Takahashi M, Ko LW, Kulathingal J, et al. Oxidative stress-induced phosphorylation, degradation and aggregation of α-synuclein are linked to upregulated CK2 and cathepsin D[J]. Eur J Neurosci, 2007, 26(4): 863–874. doi: 10.1111/j.1460-9568.2007.05736.x
    Rai SN, Tiwari N, Singh P, et al. Therapeutic potential of vital transcription factors in Alzheimer's and Parkinson's disease with particular emphasis on transcription factor EB mediated autophagy[J]. Front Neurosci, 2021, 15: 777347. doi: 10.3389/fnins.2021.777347
    He J, Zhu G, Wang G, et al. Oxidative stress and neuroinflammation potentiate each other to promote progression of dopamine neurodegeneration[J]. Oxid Med Cell Longev, 2020, 2020: 6137521. doi: 10.1155/2020/6137521
    Rai SN, Singh P, Varshney R, et al. Promising drug targets and associated therapeutic interventions in Parkinson's disease[J]. Neural Regen Res, 2021, 16(9): 1730–1739. doi: 10.4103/1673-5374.306066
    Mbefo MK, Paleologou KE, Boucharaba A, et al. Phosphorylation of synucleins by members of the Polo-like kinase family[J]. J Biol Chem, 2010, 285(4): 2807–2822. doi: 10.1074/jbc.M109.081950
    Rocha EM, De Miranda B, Sanders LH. Alpha-synuclein: Pathology, mitochondrial dysfunction and neuroinflammation in Parkinson's disease[J]. Neurobiol Dis, 2018, 109: 249–257. doi: 10.1016/j.nbd.2017.04.004
    Hoenen C, Gustin A, Birck C, et al. Alpha-synuclein proteins promote pro-inflammatory cascades in microglia: stronger effects of the A53T mutant[J]. PLoS One, 2016, 11(9): e0162717. doi: 10.1371/journal.pone.0162717
    Zhang Q, Heng Y, Yuan Y, et al. Pathological α-synuclein exacerbates the progression of Parkinson's disease through microglial activation[J]. Toxicol Lett, 2017, 265: 30–37. doi: 10.1016/j.toxlet.2016.11.002
    Rappold PM, Tieu K. Astrocytes and therapeutics for Parkinson's disease[J]. Neurotherapeutics, 2010, 7(4): 413–423. doi: 10.1016/j.nurt.2010.07.001
    Rodriguez M, Rodriguez-Sabate C, Morales I, et al. Parkinson's disease as a result of aging[J]. Aging Cell, 2015, 14(3): 293–308. doi: 10.1111/acel.12312
    Rai SN, Singh P. Advancement in the modelling and therapeutics of Parkinson's disease[J]. J Chem Neuroanat, 2020, 104: 101752. doi: 10.1016/j.jchemneu.2020.101752
    Martí Y, Matthaeus F, Lau T, et al. Methyl-4-phenylpyridinium (MPP +) differentially affects monoamine release and re-uptake in murine embryonic stem cell-derived dopaminergic and serotonergic neurons[J]. Mol Cell Neurosci, 2017, 83: 37–45. doi: 10.1016/j.mcn.2017.06.009
    Rai SN, Chaturvedi VK, Singh P, et al. Mucuna pruriens in Parkinson's and in some other diseases: recent advancement and future prospective[J]. 3 Biotech, 2020, 10(12): 522. doi: 10.1007/s13205-020-02532-7
    Trovato Salinaro A, Pennisi M, Di Paola R, et al. Neuroinflammation and neurohormesis in the pathogenesis of Alzheimer's disease and Alzheimer-linked pathologies: modulation by nutritional mushrooms[J]. Immun Ageing, 2018, 15: 8. doi: 10.1186/s12979-017-0108-1
    Mancuso C, Pani G, Calabrese V. Bilirubin: an endogenous scavenger of nitric oxide and reactive nitrogen species[J]. Redox Rep, 2006, 11(5): 207–213. doi: 10.1179/135100006X154978
    Calabrese V, Cornelius C, Dinkova-Kostova AT, et al. Cellular stress responses, the hormesis paradigm, and vitagenes: novel targets for therapeutic intervention in neurodegenerative disorders[J]. Antioxid Redox Signal, 2010, 13(11): 1763–1811. doi: 10.1089/ars.2009.3074
    Calabrese V, Mancuso C, Calvani M, et al. Nitric oxide in the central nervous system: neuroprotection versus neurotoxicity[J]. Nat Rev Neurosci, 2007, 8(10): 766–775. doi: 10.1038/nrn2214
    Goodman Y, Mattson MP. Ceramide protects hippocampal neurons against excitotoxic and oxidative insults, and amyloid β-peptide toxicity[J]. J Neurochem, 1996, 66(2): 869–872. doi: 10.1046/j.1471-4159.1996.66020869.x
    Dirnagl U, Meisel A. Endogenous neuroprotection: mitochondria as gateways to cerebral preconditioning?[J]. Neuropharmacology, 2008, 55(3): 334–344. doi: 10.1016/j.neuropharm.2008.02.017
    Miquel S, Champ C, Day J, et al. Poor cognitive ageing: Vulnerabilities, mechanisms and the impact of nutritional interventions[J]. Ageing Res Rev, 2018, 42: 40–55. doi: 10.1016/j.arr.2017.12.004
  • 加载中


    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(4)  / Tables(1)

    Article Metrics

    Article views (1722) PDF downloads(208) Cited by()
    Proportional views
    Relative Articles


    DownLoad:  Full-Size Img  PowerPoint